Chinese team finds human-derived monoclonal antibody that blocks new coronavirus infection

Chinese research teams recently published a paper online in the American journal Science saying they have found two human-derived monoclonal antibodies that can effectively block neo-coronavirus infection, which are expected to be used in the development of anti-coronary drugs and vaccines.

Chinese team finds human-derived monoclonal antibody that blocks new coronavirus infection

China Capital Medical University, Institute of Microbiology of the Chinese Academy of Sciences, Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences, Shenzhen Third People’s Hospital and other units participated in the study. The researchers isolated four human-derived monoclonal antibodies from peripheral blood mononucleiacic cells in a new coronary patient. Experiments show that these four antibodies have the neutral ity and ability to new coronaviruses. Two antibodies, called B38 and H4, respectively, can block the binding domain of the receptor of the neo-coronavirus protoprotein and its receptor, angiotensin conversion enzyme 2 (ACE2).

Chinese team finds human-derived monoclonal antibody that blocks new coronavirus infection

Previous studies that have revealed the mechanism of neo-coronavirus infection have shown that the virus is primarily infected through its surface protrusion protein receptor binding domain and ACE2 binding on human cells. Experiments showed that B38 and H4 respectively identified different epitopes of the receptor binding domain, and mouse experiments confirmed that the two antibodies could reduce the amount of virus in the lungs of infected mice, showing therapeutic effect. The two antibodies can also be mixed to more effectively suppress viral infections.

The team further analyzed the compound structure formed by the binding region of the new coronavirus protrusion protein receptor with B38, thus revealing the molecular mechanism of B38 to block viral infection.

Chinese team finds human-derived monoclonal antibody that blocks new coronavirus infection

The researchers say the latest research suggests that the two antibodies screened have the potential to be further developed to treat new coronavirus infections and provide a basis for vaccine design. At present, two antibodies have been in the relevant companies for product conversion, the future is expected to be used in the clinical treatment of new corona patients.